Brazil's Vittia lands $26.8M from Finep to build out biologicals pipeline
What's the deal? Brazilian biologicals company VittiaDealroom has a profile for this one. Try Dealroom → has secured up to US$39.1M in debt financing from FinepDealroom has a profile for this one. Try Dealroom →, Brazil's innovation funding agency. The money will fund dozens of research projects over four years, spanning biological technologies, biofertilisers, lower-impact crop protection, and animal health.
What's the endgame? The investment focuses primarily on microbiological technologies. Projects target Brazil's major crops, including metabolite-based bioinsecticides to control the brown stink bug in soybeans, biological herbicides, and specialty fertilisers.
Vittia launches two to three new technologies a year and plans to keep that pace. "Even if we had 10 or 15 ready to launch, it would not be commercially viable," said Alexandre Del Nero Frizzo, its chief financial and investor relations officer. Part of the funding will also go to improving industrial processes and cutting production costs.
Why now? Vittia is entering what Frizzo called its fourth difficult crop season, amid a downturn marked by tight producer margins. "I do not see many more seasons in this down cycle," he said. "When the turnaround will come is something nobody knows, but it will happen."
By the numbers: In the first quarter of 2026, consolidated net revenues fell 11.5% to US$31.2M, and the company posted a net loss of US$1.51M, compared with a US$486K loss a year earlier. Revenue from biological and natural solutions dropped from US$12.8M to US$11.8M, with gross margin in the segment down 10.2 percentage points to 52.5%.
Going abroad: Alongside the R&D push, Vittia has begun commercial operations in Mexico, its first structured international operation. Part of its portfolio is already registered there.
The signal: Brazil's biologicals market is entering what Frizzo describes as "massification" rather than commoditisation, with supply and competition rising sharply over the past five years. By betting on a multi-year pipeline, Vittia is wagering that quality and scale — not price — will decide who survives the squeeze.
Read more: news.agropages.com
Image credit: MIPT Photostream
